![]() | Only 14 pages are availabe for public view |
Abstract Objective: We aimed to investigate as primary endpoint whether carbetocin 100 mcg applied as a short infusion (short infusion group) had an equal effect on blood loss as compared with the effect of a slow manual injection (bolus group) Study design: Randomized controlled prospective study was done on 200 women undergoing cesarean section after 37 weeks. All patients receivedthe study drug after cord clamping. They were given either a one ml carbetocin 100 mcg manual bolus over one minute or a short infusion of 100 ml 0.9% NaCl administered as quickly as possible in a passive flow by gravity, which contained carbetocin 100 mcg. Results: Between April 2021 and October 2021, 100 patients were randomized to receive carbetocin as bolus and 100 to receive it as short infusion. The estimated amount of blood loss in the bolus group was 330.28 ± 170.93 ml and in the infusion group was 362.32 ± 187.28ml with no statistically significant difference between the two groups, BP, uterine tone, use of additional uterotonics, and side-effects were comparable. Conclusion: Administration of carbetocin as short infusion has a similar effect on blood loss during CS as a slow I.Vbolus and does not compromise uterine tone and has similar cardiovascular side effects. In accordance with current recommendations for oxytocin, carbetocin can safely be administered as short infusion during CS. |